Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.67 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BUB1 | O43683 | 8/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385072 | 0.88 | CNR2 (0.60) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL516714 | 0.87 | CNR2 (0.59) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL27800056 | 0.85 | CNR2 (0.80) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL516475 | 0.83 | CNR2 (0.54) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL27821229 | 0.81 | CNR1 (0.62) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL9917500 | 0.80 | CNR2 (1.00) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL27578623 | 0.78 | CNR2 (0.70) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL28045003 | 0.77 | CNR2 (0.68) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL516208 | 0.76 | CNR2 (0.66) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL30415447 | 0.76 | CNR2 (0.66) | CNR2CNR1ACHEBUB1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2010079120-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | CNR2 3885/4885CNR1 4392/4885ACHE 1883/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | CNR2 3885/4885CNR1 4392/4885ACHE 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.